SCHEMBL22904503

SCHEMBL22904503

CNc1cccc2c1C(=O)NC(=O)C2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 16/20 0.58
CASP3 P42574 1/20 0.51
CASP7 P55210 1/20 0.51
CASP9 P55211 1/20 0.51
CASP6 P55212 1/20 0.51
CASP8 Q14790 1/20 0.51
MAP3K14 Q99558 1/20 0.51
AHR P35869 2/20 0.42
PDK2 Q15119 1/20 0.42
EGFR P00533 1/20 0.41
MAPT P10636 1/20 0.41
PABPC1 P11940 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22904358 0.83 TDP2 (0.54) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904136 0.81 ALDH1A1 (0.60) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904353 0.81 TDP2 (0.53) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904526 0.80 TDP2 (0.54) TDP2CASP3CASP7CASP9CASP6
SCHEMBL20886849 0.77 TDP2 (0.64) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904296 0.76 TDP2 (0.50) TDP2CASP3CASP7CASP9CASP6
SCHEMBL24029524 0.75 TDP2 (0.49) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904178 0.74 TDP2 (0.64) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904158 0.74 TDP2 (0.64) TDP2CASP3CASP7CASP9CASP6
SCHEMBL11565330 0.74 TDP2 (0.64) TDP2CASP3CASP7CASP9CASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021011631-A1 FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-01-21 WO disclosed